Veterinary And Comparative Oncology | FACULTY OF VETERINARY MEDICINE
» RESEARCH » RESEARCH NICHE AREAS » VETERINARY AND COMPARATIVE ONCOLOGY

Veterinary and Comparative Oncology


Programmee Leader

1. Professor Dr .Rasedee Abdullah - Haematology and Clinical Biochemistry Veterinary Medicine

Co-Researcher

2. Professor Dr. Noordin Mustapha - Veterinary Pathology
3. Professor Dato' Dr. Mohd. Azmi M.Lila - Virology
4. Professor Dr. Tengku Azmi Tengku Ibrahim - Histology
5. Dr. Gayathri Thevi Selvarajah - Small Animal Medicine (Oncology)
6. Assoc. Professor Dr. Hazilawati Hamzah Senior - Veterinary Clinical Pathology
7. Assoc. Professor Dr. Mohd. Hezmee Mohd Noor  - Veterinary Pharmacology

Synopsis

The main research areas are in the investigation of mechanisms of development, detection, monitoring, and treatment of animal cancers. The mechanisms of cancer development are investigated by determining pathways and molecules involved in cancer proliferation and regression. These pathways and molecules will serve as targets for intervention and induction therapies for cancers. In the early detection and monitoring of cancer development, several serum biomarkers have been identified, which have potential to be developed into diagnostic kits.

The efficacies of new anticancer synthetic and natural compounds are aso investigated in dogs, cats, mice and rats with natural occurring and induced cancers. Some of these compounds will be packaged in new and innovative nanoparticle delivery systems for more effective therapies.

The research also involves preclinical trials in the development of animal and human cancer therapeutics that would eventually culminate in commercialization.


Keywords : animal cancer, biomarkers, therapeutics

Research Highlights

  • Cancer studies in companion animals as a spontaneous model for human cancer types. Determination of molecular and pathological basis of cancer development in companion and experimental animals. Determination of epidemiological and genetic causes of animal cancers.
  •  Development of pure and particle-loaded natural products for treatment of cancers. Patent-pending products for treatment of cancers developed by the group include, hydroxypropyl-β-cyclodextrin-zerumbone inclusion complex, thymoquinone-loaded nanostructured nanoparticles, zerumbone-loaded nanostructured nanoparticles.
  • Contribution to the development of an up-to-date research facility (LIVES) in UPM.
  • Published more than 100 technical papers and won awards in several scientific expositions.
  • Collaborative research activities with Utrecht University, Netherlands, University Malaya and Nottingham University, Malaysia campus.


Current Research Grant

  1. Development of Drug/Compound-loaded nanoparticles. MOSTI. RM 300,000
  2. Complete toxicity profile of thymoquinone-nanostructured lipid carrier (TQ-NLC): A requirement for human clinical trial. RUGS. RM230,000
  3. Establishment of Mechanism of Tumour Regression Through Complement Mediated Inflammatory Reaction of C5a-C5aR Axis. MOSTI. RM250,000
  4. Development of Complement C5a and its Receptor (C5aR) as a Mammary Tumour Biomarker. ERGS. RM195,000.
  5. The expression and clinicopathological relevance of fibroblast growth factor receptors in canine mammary gland tumours. RUGS. 32,000.
  6. The clinicopathological significance of vitamin D signaling in canine and feline tumours. RUGS. RM30,000.
  7. Expression of complement anaphylatoxin 5a receptor (c5ar) and measurement of its magnitude in spontaneous canine tumours. RUGS. RM30,000.
  8. Synergistic Effects of Local Herbs in Inhibiting Angiogenesis in Leukaemia-Lymphoma Rats. MOSTI RM177,580. 9. Role of Local Herbs in Regulating Haematological Malignancy Biomarkers. FRGS. RM119,000.

 

Recent Publications

1. Ismail AA, Chung YL, Ahmad Bustamam Abdul, Cheah FK, Wong WF, Sukari MA, Rasedee Abdullah, Syam M, Suvita S, A Arya, Elhassa Taha MM, Muharram B, Musatafa MR and Abdelwahab SI (2012). Dentatine induces apoptosis in prostate cancer cells via BcL-2, Bcl-xL, Survivin downregulation, caspase-9, -3/7 activation and NF-κB inhibition. Evidence-Based Complementary and Alternative Medicine. doi:10:1155/2012/856029.

2. Elthayeb EM Eid, Ahmad Bustamam Abdul, Fakhr Eldin O. Suliman, Mohd A. Sukari, Rasedee Abdullah and Safa S. Fatah (2011). Characterization of the inclusion complex of zerumbone with hydroxypropyl-β-cyclodextrin. Carbohydrate polymers 83: 1707-1714.

3. Selvarajah GT, Verheije MH, Kik M, Slob A, Rottier PJ, Mol JA, Kirpensteijn J. (2012). Expression of epidermal growth factor receptor in canine osteosarcoma: Association with clinicopathological parameters and prognosis. Veterinary Journal 193(2):412-419.

4. Mohd Hezmee MN, Kyaw-Tanner M, Lee Ian, Shiels A, Rolfe B, Woodruff T and Mills PC (2011). Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors. Veterinary Immunology and Immunopathology 139 (1): 50-56.

5. Manal Mohamed Elhassan Taha, Ahmad Bustamam Abdul, Rasedee Abdullah, Tengku Azmi Tengku Ibrahim, Siddig Ibrahim Abdelwahab and Syam Mohan (2010). Potential chemoprevention of diethynitrosamine-initiated and 2-acetylaminofluorent-promoted hepatocarcinogenesis by zerumbone from the rhizomes of the subtropical ginger (Zingiber zerumbet). Chemico-biological Interactions, 183(3): 295-305.

Updated:: 24/05/2017 [mjamil]

MEDIA SHARING

FACULTY OF VETERINARY MEDICINE
Universiti Putra Malaysia
43400 UPM Serdang
Selangor Darul Ehsan
+603 8609 3890
+603 8947 1971
C1500612180